Tuberculosis and HIV co-infection in children

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages

  Venturini, Elisabetta ^a   Turkova, Anna ^b   Chiappini, Elena ^a   Galli, Luisa ^a   de Martino, Maurizio ^a   Thorne, Claire ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; ISONIAZID; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; RIFABUTIN; RIFAPENTINE;

BACTERIAL INFECTION; BACTERIUM CULTURE; BCG VACCINATION; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNODEFICIENCY; CHILD; DISEASE SEVERITY; DISSEMINATED BCG DISEASE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION SENSITIVITY; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NASOPHARYNGEAL ASPIRATION; OUTCOME ASSESSMENT; PATHOGENESIS; PERINATAL INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS LOAD;

EID: 84989339629     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S1-S5     Document Type: Review

References (88)

1. World Health Organization: Global tuberculosis report 2012.[http://apps. who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf].
2. Global report: UNAIDS report on the global AIDS epidemic 2013. [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf].
3. Time to act. Save a million lives by 2015. Prevent and treat tuberculosis among people living with HIV. [http://www.stoptb.org/assets/documents/resources/publications/acsm/TB_HIV_Brochure_Singles.pdf].
4. Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, Venkatesan P, Prabhakar R, Datta M: Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 2000, 4:839-844.
5. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O, EuroSIDA study group: Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS 2011, 25:1505-1513.
6. Marais BJ, Rabie H, Cotton MF: TB and HIV in children-advances in prevention and management. Paediatr Respir Rev 2011, 12:39-45.
7. World Health Organization: Global HIV/AIDS response. Progress report 2011.[http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf].
8. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM, Collaborative HIV Paediatric Study (CHIPS), National Study of HIV in Pregnancy and Childhood (NSHPC): Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007, 45:918-924.
9. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284:190-197.
10. Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd, Pediatric AIDS Clinical Trials Group 219/219C Study Team: Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year followup study. Clin Infect Dis 2008, 46:507-515.
11. KIDS-ART-LINC Collaboration: Low risk of death, but substantial program attrition in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008, 49:523-531.
12. Lumbiganon P, Kariminia A, Aurpibul L, Hansudewechakul R, Puthanakit T, Kurniati N, Kumarasamy N, Chokephaibulkit K, Nik Yusoff NK, Vonthanak S, Moy FS, Razali KA, Nallusamy R, Sohn AH, TREAT Asia Pediatric HIV Observational Database (TApHOD): Survival of HIV-infected children: a cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr 2011, 56:365-371.
13. Global update on HIV treatment 2013: results, impacts and opportunities. [http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734_eng.pdf].
14. Luo C, Chintu C, Bhat G, Raviglione M, Diwan V, DuPont HL, Zumla A: Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen. Tuber Lung Dis 1994, 75:110-115.
15. Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA: High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011, 11:28.
16. Karande S, Bhalke S, Kelkar A, Ahuja S, Kulkarni M, Mathur M: Utility of clinically-directed selective screening to diagnose HIV infection in hospitalized children in Bombay, India. J Trop Pediatr 2002, 48:149-155.
17. Matos TP, Kritski AL, Ruffino Netto A: Epidemiological aspects of tuberculosis in children and adolescents in Rio de Janeiro. J Pediatr (Rio J) 2012, 88:335-340.
18. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M, Tameris M, Geldenhuys H, Hanekom W, Hussey G: Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. Int J Tuberc Lung Dis 2010, 14:149-154.
19. Espinal MA, Reingold AL, Pérez G, Camilo E, Soto S, Cruz E, Matos N, Gonzalez G: Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:155-159.
20. Jeena PM, Pillay P, Pillay T, Coovadia HM: Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 2002, 6:672-678.
21. Mukadi YD, Wiktor SZ, Coulibaly IM, Coulibaly D, Mbengue A, Folquet AM, Ackah A, Sassan-Morokro M, Bonnard D, Maurice C, Nolan C, Kreiss JK, Greenberg AE: Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Côte d'Ivoire. AIDS 1997, 11:1151-1158.
22. Cohen JM, Whittaker E, Walters S, Lyall H, Tudor-Williams G, Kampmann B: Presentation, diagnosis and management of tuberculosis in HIV-infected children in the UK. HIV Med 2008, 9:277-284.
23. Thomas P, Bornschlegel K, Singh TP, Abrams EJ, Cervia J, Fikrig S, Lambert G, Mendez H, Kaye K, Bertolli J: Tuberculosis in human immunodeficiency virus-infected and human immunodeficiency virusexposed children in New York City. The New York City Pediatric Spectrum of HIV Disease Consortium. Pediatr Infect Dis J 2000, 19:700-706.
24. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ: Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr 2008, 8:1.
25. Jensen J, Álvaro-Meca A, Micheloud D, Díaz A, Resino S: Reduction in mycobacterial disease among HIV-infected children in the highly active antiretroviral therapy era (1997-2008). Pediatr Infect Dis J 2012, 31:278-283.
26. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S: How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005, 191:150-158.
27. Geldmacher C, Zumla A, Hoelscher M: Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS 2012, 7:268-275.
28. Naing C, Mak JW, Maung M, Wong SF, Kassim AI: Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis. Lung 2013, 191:27-34.
29. Patel NR, Swan K, Li X, Tachado SD, Koziel H: Impaired M. tuberculosismediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. J Leukoc Biol 2009, 86:53-60.
30. Pontillo A, Carvalho MS, Kamada AJ, Moura R, Schindler HC, Duarte AJ, Crovella S: Susceptibility to Mycobacterium tuberculosis infection in HIVpositive patients is associated with CARD8 genetic variant. J Acquir Immune Defic Syndr 2013, 63:147-151.
31. WHO, UATLD: Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: Recommendations for a public health approach.[http://www.theunion. org/index.php/en/resources/technical-publications/item/759-guidance-fornational-tuberculosis-and-hiv-programmes-on-the-management-oftuberculosis-in-hiv-infected-children-recommendations-for-a-public-healthapproach].
32. Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, Kraft CS: Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis 2012, 55:75-81.
33. Soeters M, de Vries AM, Kimpen JL, Donald PR, Schaaf HS: Clinical features and outcome in children admitted to a TB hospital in the Western Cape-the influence of HIV infection and drug resistance. S Afr Med J 2005, 95:602-606.
34. Chan SP, Birnbaum J, Rao M, Steiner P: Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1996, 15:443-447.
35. Hesseling AC, Westra AE, Werschkull H, Donald PR, Beyers N, Hussey GD, El-Sadr W, Schaaf HS: Outcome of HIV infected children with culture confirmed tuberculosis. Arch Dis Child 2005, 90:1171-1174.
36. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G: Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005, 365:130-134.
37. Moore HA, Apolles P, de Villiers PJ, Zar HJ: Sputum induction for microbiological diagnosis of childhood pulmonary tuberculosis in a community setting. Int J Tuberc Lung Dis 2011, 15:1185-1190.
38. European Centre for Disease Prevention and Control: World Tuberculosis Day 2011. Three key messages on childhood tuberculosis. Key message
39. Stockholm. 2011 [http://ecdc.europa.eu/en/publications/Publications/1103_TB_SUR_2009.pdf].
40. WHO Information note 2013. Xpert MTB/RIF increases timely TB detection among people living with HIV and saves lives. [http://www. who.int/tb/challenges/hiv/Xpert_TBHIV_Information_Note_final.pdf].
41. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, Boehme CC, Zemanay W, Zar HJ: Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011, 11:819-824.
42. Bates M, O'Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, Kasonde R, Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A: Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013, 13:36-42.
43. Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP: Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF Assay: a pilot study. Pediatr Infect Dis J 2012, 31:1316.
44. Nicol MP, Spiers K, Workman L, Isaacs W, Munro J, Black F, Zemanay W, Zar HJ: Xpert MTB/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children. Clin Infect Dis 2013, 57:18-21.
45. Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, Allen V, Boehme CC, Zemanay W, Nicol MP: Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012, 55:1088-1095.
46. Lawn SD, Kerkhoff AD, Vogt M, Wood R: Diagnostic accuracy of a lowcost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209.
47. Denkinger CM, Dheda K, Pai M: Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011, 17:806-814.
48. Mandalakas AM, Detjen AK, Hesseling AC: Can we accurately diagnose tuberculosis infection in children? Pediatr Infect Dis J 2011, 30:817-818.
49. Mandalakas AM, van Wyk S, Kirchner HL, Walzl G, Cotton M, Rabie H, Kriel B, Gie RP, Schaaf HS, Hesseling AC: Detecting tuberculosis infection in HIVinfected children: a study of diagnostic accuracy, confounding and interaction. Pediatr Infect Dis J 2013, 32:111-118.
50. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A: Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004, 364:2196-2203.
51. Davies MA, Connell T, Johannisen C, Wood K, Pienaar S, Wilkinson KA, Wilkinson RJ, Zar HJ, Eley B, Beatty D, Curtis N, Nicol MP: Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. AIDS 2009, 23:961-969.
52. Ramírez-Cardich ME, Kawai V, Oberhelman RA, Bautista CT, Castillo ME, Gilman RH: Clinical correlates of tuberculosis co-infection in HIV-infected children hospitalized in Peru. Int J Infect Dis 2006, 10:278-281.
53. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J: Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J 2002, 21:1053-1061.
54. Whittaker E, Zar HJ: Promising directions in the diagnosis of childhood tuberculosis. Expert Rev Respir Med 2012, 6:385-395.
55. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, Kasolo F, Mwaba P, Bhat G, Terunuma H, Zumla A, UNZA-UCLMS Project Paediatric Post-mortem Study Group: Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002, 360:985-990.
56. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F: Antiretroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009, 38:1612-1621.
57. Abuogi LL, Mwachari C, Leslie HH, Shade SB, Otieno J, Yienya N, Sanguli L, Amukoye E, Cohen CR: Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya. Int J Tuberc Lung Dis 2013, 17:1291-1297.
58. Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M, Violari A, Gray GE, Chaisson RE, McIntyre JA, Meyers T: HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis 2009, 13:862-867.
59. Dangor Z, Izu A, Hillier K, Solomon F, Beylis N, Moore DP, Nunes MC, Madhi SA: Impact of the Antiretroviral Treatment Program on the Burden of Hospitalization for Culture-confirmed Tuberculosis in South African Children: A Time-series Analysis. Pediatr Infect Dis J 2013, 32:972-977.
60. World Health Organisation: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013 [http://apps.who. int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf].
61. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q: Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
62. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE, CAMELIA (ANRS 1295-CIPRA KH001) Study Team: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
63. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, AIDS Clinical Trials Group Study A5221: Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
64. Yotebieng M, Van Rie A, Moultrie H, Cole SR, Adimora A, Behets F, Meyers T: Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 2010, 24:1341-1349.
65. Food and Drug Administration (U.S.): Sustiva (efavirenz) pediatric patients labeling update. 2013 [http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm350744.htm].
66. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM: Effect of rifampicin on lopinavir pharmacokinetics in HIVinfected children with tuberculosis. J Acquir Immune Defic Syndr 2008, 47:566-569.
67. Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T: Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One 2011, 6:17273.
68. Shah I, Swaminathan S, Ramachandran G, Kumar AK, Goray A, Chaddha U, Tayal S, Lala M: Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy. Indian Pediatr 2011, 48:943-947.
69. ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M, Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C, Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM: Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013, 381:1391-1403.
70. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G, Tugela Ferry Care and Research (TF CARES) Collaboration: Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 2007, 196(Suppl 3):482-490.
71. Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, Seung KJ: Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One 2012, 7:37114.
72. Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, Gandhi NR, Friedland G, Shah NS: Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis 2010, 14:1244-1251.
73. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS: Cultureconfirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012, 54:157-166.
74. Schaaf HS, Marais BJ: Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011, 12:31-38.
75. Poorana Ganga Devi NP, Swaminathan S: Drug-resistant tuberculosis: pediatric guidelines. Curr Infect Dis Rep 2013, 15:356-363.
76. USAID: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of drug-resistant tuberculosis in children: a field guide. 2012 [http://sentinelproject.files.wordpress.com/2012/11/sentinel_project_field_guide_2012.pdf].
77. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS: High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 2013, Epub ahead of print.
78. Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M, Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX, CAMELIA (ANRS 1295-CIPRA KH001) Study Team: Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013, 27:2577-2586.
79. Leroy V, Msellati P, Lepage P, Batungwanayo J, Hitimana DG, Taelman H, Bogaerts J, Boineau F, Van de Perre P, Simonon A: Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:415-421.
80. Donald PR, Marais BJ, Barry CE 3rd: Age and the epidemiology and pathogenesis of tuberculosis. Lancet 2010, 375:1852-1854.
81. Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Britton S, Feleke Y, Källenius G, Lindquist L: Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: clinical, diagnostic and epidemiological characteristics. Scand J Infect Dis 2002, 34:331-337.
82. Pillay T, Sturm AW, Khan M, Adhikari M, Moodley J, Connolly C, Moodley D, Padayatchi N, Ramjee A, Coovadia HM, Sullivan JL: Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 coinfection. Int J Tuberc Lung Dis 2004, 8:59-69.
83. Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, Joshi S, Khandekar M, Karmarkar A, Kulkarni V, Sastry J, Mave V, Suryavanshi N, Thakar M, Kulkarni S, Tripathy S, Sambarey P, Patil S, Paranjape R, Bollinger RC, Jamkar A, Six Week Extended-Dose Nevirapine (SWEN) India Study Team: Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis 2011, 203:358-363.
84. Adhikari M, Jeena P, Bobat R, Archary M, Naidoo K, Coutsoudis A, Singh R, Nair N: HIV-Associated Tuberculosis in the Newborn and Young Infant. Int J Pediatr 2011, 2011:354208.
85. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ: Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007, 334:136.
86. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C, P1041 Study Team: Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011, 365:21-31.
87. Report of the HIV/TB Research meeting held in conjunction with the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013). [http://www.who.int/tb/challenges/hiv/tbhiv_at_croi_2013_report. pdf].
88. The PREVENT TB Study. Rifapentine + isoniazid to prevent TB among people living with HIV: interim data and pending issues. [http://www. who.int/tb/challenges/hiv/sterling_prevent_tb_study_26_hiv_croi_03mar2013.pdf].